Liarozole dihydrochloride | 1883548-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: Liarozole dihydrochloride
• 英文别名: 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole;dihydrochloride
• CAS: 1883548-96-6
• 化学式: C17H15Cl3N4
• 分子量: 381.7
• InChiKey: NKDMRTVUEJWCCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.89
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  46.5
• 氢给体数：
  3
• 氢受体数：
  2

文献信息

• CARGOMERS
  申请人：Abionyx Pharma SA

  公开号：EP3668600A1

  公开（公告）日：2020-06-24
• COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS
  申请人：The Regents of the University of Michigan

  公开号：US20180250419A1

  公开（公告）日：2018-09-06

  The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).
• Methods of Producing Specialized Cardio-Like Cells from Stem Cells
  申请人：Emory University

  公开号：US20190136191A1

  公开（公告）日：2019-05-09

  This disclosure relates to method of differentiating stem cells to specific cardiac-like cells. In certain embodiments, the disclosure contemplates methods of generating left ventricular-like cells and the atrial-like cells by timing the exposure of dividing stem cells to retinoic acid (RA) or retinoic acid receptor inhibitors.
• [EN] COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'AFFECTIONS CARDIOVASCULAIRES
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2016154542A2

  公开（公告）日：2016-09-29

  The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).
• [EN] CARGOMERS<br/>[FR] CARGOMÈRES
  申请人：CERENIS THERAPEUTICS HOLDING

  公开号：WO2019030574A1

  公开（公告）日：2019-02-14

  Cargomers comprising apolipoprotein molecules complexed with amphipathic molecules and one or more cargo moieties.